Im Milliardenmarkt für Abnehmspritzen verklagt der dänische Pharmakonzern seinen US-Rivalen: Dessen Werbung täusche Verbraucher mit veralteten Vergleichen, so der Vorwurf.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.